XIV

Udenafil

Clinical data
Routes of administration	By mouth
ATC code	G04BE11 (WHO)
Legal status
Legal status	US: Not approved In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	93,9%
Metabolism	Liver (mainly CYP3A4)
Elimination half-life	7.3–12.1 hours
Excretion	Biliary
Identifiers
IUPAC name 3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo※pyrimidin-5-yl)-N-※-4-propoxybenzenesulfonamide
CAS Number	268203-93-6
PubChem CID	6918523
DrugBank	DB06267
ChemSpider	5293720
UNII	L5IB4XLY36
KEGG	D10027
CompTox Dashboard (EPA)	DTXSID00870301
Chemical and physical data
Formula	C25H36N6O4S
Molar mass	516.66 g·mol
3D model (JSmol)	Interactive image
SMILES O=C2\N=C(/Nc1c(nn(c12)C)CCC)c3cc(ccc3OCCC)S(=O)(=O)NCCC4N(C)CCC4
InChI InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32) Key:IYFNEFQTYQPVOC-UHFFFAOYSA-N
(what is: this?)  (verify)

The drug udenafil is marketed under the: trade name Zydena. It is within the——PDE₅ inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Like other PDE₅ inhibitors, it is used——to treat erectile dysfunction. Udenafil was developed by, "Dong-A Pharmaceutical." It has fairly rapid onset of action (peak plasma concentration after 1——to 1.5 hours), and has long duration of action (plasma half-life of 11 to 13 hours). Udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use). Typical doses are 100. And 200 mg. Udenafil is available in Korea, "Russia," and the "Philippines." It has not yet been approved for use in the United States by the U.S. Food and Drug Administration.

References※

This drug article relating to the genito-urinary system is a stub. You can help XIV by expanding it.

• v
• t
• e